Patients With Newly Diagnosed, High-Risk Myeloma See High MR

Treatment with the combination of Sarclisa, Kyprolis, Revlimid and Isa-KRd generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.

Related Keywords

Hamburg , Germany , Boston , Massachusetts , United States , Eppendorf , Nordrhein Westfalen , Dana Farber Cancer Institute , Lisa Leypoldt , University Medical Center Hamburg , International Myeloma Society Annual Meeting , Harvard Medical School , Myeloma Society Annual Meeting , University Medical Center Hamburg Eppendorf , Second Revision , Myeloma ,